March 18, 2024
I hate to answer a question with a question; yet, are we just helping the oversold get to being overbought and subject to electronic trading?
Pre-open Indication: 1 Sell into Strength, 4 Positive and 1 Negative Indications
Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading! Join me … in the NO spin zone and new website!
Never leave an investor uninformed!
March 18, 2024
A scorecard of earnings releases of covered companies -
The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status".
26 of 35 covered released to date
March 18, 2024
As electronic trading including algorithms sell into strength brought-on by Friday’s triple-witching “covering”
Earnings: Adverum Biotechnologies (ADVM) <see The Bottom Line>
Pre-open Indications: 2 Hit and 4 Miss
The Harvard Apparatus RT (OTC QB HRGN) formerly Biostage (BSTG) Chronicles: Question, Is it a Ponzi Scheme?
Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading! A 360-degree review of the who, why, when and what happened in the sector as the market and economics surround your portfolio defense.
Never leave an investor uninformed! A trusted source of factual reporting!
March 18, 2024
A scorecard of earnings releases of covered companies - The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status". 26 of 35 covered released to date
March 18, 2024
Blue closed up, Friday +$0.09 to $1.42 and is up +$0.03 or +2.115 pre-open Funding expected to extend BLUE’s cash runway until Q1/26 $75 million was drawn down upon closing; BLUE will be eligible to draw an additional $50 million subject to achievement of commercial milestones -
March 6, 2024
Size: 4.65 M shares, 1.521 (pre-funded at $22.9999)) warrents with gross of $140 M before the "usual" deductions with an option to purchase 913,050 shares again less discounts and commissions Stock dropped -$0.61 to $24.00 with a -$0.79 or -3.29% aftermarket indication Close expected by 3/11 ... Morgan Stanley, Goldman Sachs & Co. LLC, Barclays and Stifel are acting as joint book-running managers of the offering.
6 hours 59 min ago
RegMed Investors (RMi) - Q4/23 & FY23 Cell and Gene Therapy Earnings Scorecard Results
7 hours 4 min ago
RegMed Investors (RMi) Closing Bell: a session of cell and gene therapy sector shifting share pricing
14 hours 17 min ago
RegMedInvestors (RMi) Research Note – finance: bluebird bio (BLUE)Secures up to $175 M Debt Financing with Hercules Capital
16 hours 9 min ago
RegMed Investors’ (RMi) pre-open: which way to safety?